CSL

Australia’s biotechnology firm CSL has completed the acquisition of global influenza vaccine business from Novartis for around $275m.

The deal was first announced by both firms in October 2014.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CSL will incorporate the acquired business in its subsidiary bioCSL, as the transaction concluded.

The combined business is claimed to be the second largest influenza vaccine business in the $4bn global industry.

With manufacturing facilities in the US, UK, Germany and Australia, the business includes differentiated product portfolio and strong pandemic and pre-pandemic franchises in around 20 countries.

See Also:

"This will transform bioCSL’s existing influenza vaccine business, giving us first class facilities, global scale and product and geographical diversity."

According to CSL, the combined business will complete all clinical programmes underway and market all bioCSL and Novartis influenza vaccine brands in various markets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The combined business will continue to in-licence and supply a wide range of vaccines and specialty pharmaceuticals, as well as produce blood typing reagents for local use in Australia.

It will also continue to produce anti-venoms and Q fever vaccine, claimed to be the world’s only supplier of these Australian medicines.

At the time of acquisition, bioCSL general manager Dr John Anderson said: "This will transform bioCSL’s existing influenza vaccine business, giving us first class facilities, global scale and product and geographical diversity.

"bioCSL is absolutely focused on its critical role as Australia’s onshore supplier of influenza vaccine, which underpins its pivotal position in both the nation’s influenza pandemic preparedness and swift seasonal responses to influenza."

Image: Novartis headquarters in Basel. Photo: courtesy of Andrew.